Synthesis and cellular characterization of various nano-assemblies of cell penetrating peptide-epirubicin-polyglutamate conjugates for the enhancement of antitumor activity by Mohammadi, Samaneh et al.
 1 
 
Synthesis and cellular characterization of various nano-
assemblies of cell penetrating peptides-epirubicin-polyglutamate 
conjugates for enhancement of antitumor activity  
 
Samaneh Mohammadi1, Parvin Zakeri-Milani2, Nasim Golkar3,4, Samad Mussa Farkhani1,5, 
Ali Shirani1,5, Javid Shahbazi Mojarrad2, Ali Nokhodchi6, Hadi Valizadeh7* 
 
Affiliations: 
1Biotechnology Research Center and Faculty of Advanced Medical Sciences, Tabriz 
University of Medical Sciences, Tabriz, Iran. 
2Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz 
University of Medical Sciences, Tabriz, Iran. 
3Pharmaceutics Department, School of Pharmacy, Shiraz University of Medical Sciences, 
Shiraz, Iran.  
4Pharmaceutical Science Research Center, Shiraz University of Medical Science, Shiraz, Iran. 
5Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 
6Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex, Arundel 
Building, Brighton BN1 9QJ, UK. 
7Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical 
Sciences, Tabriz, Iran. 
 
*To whom correspondence should be addressed: 
Dr. Hadi Valizadeh, PharmD, PhD, Professor, 
Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical 
Sciences, Tabriz, Iran. 51664. 
E-mail: valizadeh@tbzmed.ac.ir 
Phone: +98 (41) 3339-2649 
Fax: +98 (41) 3334-4798   
 2 
 
Synthesis and cellular characterization of various nano-
assemblies of cell penetrating peptides-epirubicin-polyglutamate 
conjugates for enhancement of antitumor activity  
Abstract 
A new class of cell penetrating peptides (CPPs) named peptide amphiphile was designed to 
improve the intracellular uptake and antitumor activity of epirubicin (EPR).  Various 
amphiphilic CPPs were synthesized by solid phase peptide synthesis method and were 
chemically conjugated to EPR. Their corresponding nanoparticles (CPPs-E4 and CPPs-E8) 
were prepared via non-covalent binding of the peptides and polyanions. Cytotoxicity and 
anti-proliferative activity were evaluated by MTT assay. Cellular uptake was examined by 
flow cytometry and fluorescence microscopy. The CPPs exhibited slight cytotoxicity. 
Binding of polyglutamate to CPPs (CPPs-E4 and CPPs-E8 nanoparticles) decreased their 
cytotoxicity. CPPs-E8 nanoparticles showed lower cytotoxicity than CPPs-E4 nanoparticles. 
Cellular uptake of K3W4K3-E8, K2W4K2-E8 and W3K4W3-E8 reached 100% with no 
difference between each of the mentioned CPPs and its nanoparticle at 50 µM. The anti-
proliferative activity of EPR was enhanced following conjugation to peptides and 
nanoparticles at 25 µM. CPPs-EPR-E4 and –E8 nanoparticles displayed higher anti-
proliferative activity than CPPs-EPR at 25 µM. CPPs–E8-EPR nanoparticles showed higher 
anti-proliferative activity than CPPs–E4-EPR. K3W4K3-E8-EPR nanoparticles exhibited the 
highest anti-proliferative activity at 25 µM. The synthesized peptide nanoparticles are 
proposed as suitable carriers for improving the intracellular delivery of EPR into tumor cells 
with low cytotoxicity and high antitumor activity. 
Key words: Cell penetrating peptides, epirubicin, solid phase peptide synthesis, glutamate, 
nanoparticles, drug delivery 
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1. Introduction 
Despite vast advances about anticancer drugs during the last decade, cancer is still one of the 
important worries of the world [1, 2]. Ineffective accumulation of drugs in tumors, lack of 
tumor specificity, heterogeneity of cancer cells, drug toxicity and drug resistance are factors 
that causes the lack of efficiency in cancer therapy [1, 3, 4].  
Epirubicin (EPR) is an anthracycline drug that has been used alone or in combination with 
other drugs for treatment of various cancers such as breast, ovarian, gastric and lung [5, 6]. 
EPR is a stereoisomer of doxorubicin and is flavoured over it. It has been shown that EPR is 
generally more successful than doxorubicin due to the higher tumor therapeutic efficiency  
and less side effects [7, 8]. In fact, as a consequence of the reorientation of the hydroxyl 
group in the 4'-position of the daunosamine ring, epirubicin finds different pharmacologic 
properties than doxorubicin [9]. First, it has a lower pKa. Accordingly, it is more lipophilic 
and better able to penetrate cells. Second, the glucuronidation of epirubicin and epirubicinol 
to inactive metabolites leads to a shorter terminal half-life for epirubicin (30 hours) compared 
with doxorubicin (45 hours) [8, 9]. Third, higher doses of epirubicin are required to produce 
the same degree of toxicity as doxorubicin. The doxorubicin-epirubicin dose ratios for similar 
toxicities are 1:1.2 for hematologic, 1:1.5 for nonhematologic, and 1:1.8 for cardiac [8, 10].  
Although EPR exhibited activity in all phases of the cell cycle but it was active mostly in S 
and G2 phases. The antineoplastic effect of epirubicin occurs through a number of 
mechanisms. First, it intercalates between DNA nucleotide base pairs, resulting in the 
inhibition of DNA, RNA, and protein synthesis. Second, the intercalation leads to 
topoisomerase II cleavage of DNA, which results in cytocidal activity. Third, epirubicin 
inhibits DNA helicase activity, which ultimately interferes with replication and transcription 
[10, 11]. Various experiments have shown that EPR inhibits cell proliferation and DNA 
synthesis in various carcinoma cell lines. Although fewer, like chemotherapy drugs, EPR still 
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shows side effects such as cardio toxicity and myelosuppression [7]. Development of 
resistance to a certain dose of anticancer drugs is another major limitation of EPR. EPR is a 
hydrophilic drug with high volume of distribution [11].  
Drug delivery systems modify the efficacy and toxicity of anticancer drugs. Moreover, drug 
delivery systems can avoid multi drug resistance (MDR) created through factors such as P-
glycoprotein and multi drug resistance proteins (MRPs) [12, 13, 14, 15, 16, 17]. Chemical 
conjugation with a parent drug as “Prodrug” strategy is one of the drug delivery systems that 
has been widely used in EPR delivery [12]. Several methods have been used to improve EPR 
delivery, including using nanodiamond [18], SLN (solid lipid nanoparticles) [19], 
phospholipids as multi drug resistance modulators of the epirubicin transport [20], carbon 
nanoparticles [21], and PLGA nanoparticles [22]. 
Peptides and proteins are generally worthy in many aspects, such as their possible high 
potency, good selectivity and acceptable toxicity [23]. Two decades ago, a new kind of 
peptides, commonly known as cell penetrating peptides (CPPs), was discovered. They have 
been extracted from natural proteins and have the capability to cross cellular membranes and 
mediate the uptake of a wide range of macromolecular cargoes [1, 24, 25, 26, 27]. The 
discovered peptides as non-invasive vectors with very limited toxicity introduced a novel 
field in drug delivery [28]. In addition, they can be modiﬁed or designed de novo. They are 
typically short; usually 5–30 amino acids long [27, 29, 30, 31, 32, 33, 34]. These bioactive 
and biodegradable peptides are able to carry and deliver their cargoes such as nucleic acids, 
proteins, drugs, or imaging agents, to the cytoplasm or nuclei of cells [29, 32, 33, 34]. In the 
recent years, numerous natural and synthetic CPPs such as polyarginines, TAT (trans-acting 
activator of transcription) [26] and peptide amphiphiles (PA) [22] have improved the cellular 
uptake of various drugs such as Taxol [35], methotrexate [16], and doxorubicin [12]. Among 
these CPPs, peptide amphiphiles appear to be among efficient systems in drug delivery [36, 
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37, 38]. Universally, peptide amphiphiles consist of hydrophobic segments such as 
tryptophan and charged segments such as arginine or lysine [36]. These peptides have a 
helical secondary structure with the hydrophobic and hydrophilic domains. They use the 
charged region for cell membrane interaction and the hydrophobic region for membrane 
perturbation and translocation [29, 39]. Moreover, several studies have shown that the 
presence of tryptophan and backbone spacing can affect the uptake efficiency as well as its 
mechanism [40]. 
In the present study several novel CPPs based on different designs containing lysine and 
tryptophan were synthesized. Highly active EPR (instead of Doxorubicin) was utilized as a 
drug. These peptides were then conjugated to EPR to improve the antitumor activity of the 
drug in MCF-7 breast cell line. Their corresponding nano-assemblies were prepared by non-
covalent binding of the peptides and polyglutamate, with two different chain lengths. Finally, 
cytotoxicity, intracellular uptake and antitumor activity of the synthesized peptides as well as 
their nanoparticles were investigated and compared.  
2. Materials and Methods  
2.1. Materials 
Classical glass reaction vessels suitable for performing solid-phase peptide synthesis (SPPS) 
were made by glassblowers. All of the amino acids (lysine, tryptophan and glutamate) and 
Rink amid-resin were purchased from Aapptec [15]. N, N, N′, N′-Tetramethyl-O-
(benzotriazol-1-yl) uraniumtetrafluoroborate (TBTU) and N,Ndiisopropylethylamine 
(DIPEA) as coupling reagents, dichloromethane (DCM) and N,N dimethyl formamide (DMF) 
as activating reagents, phenol and triisopropylsilane (TIS) as scavengers, trifluoroacetic acid 
(TFA), fluorescein isothiocyanate (FITC), 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were all obtained from 
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Sigma-Aldrich [15]. Potassium cyanide (KCN), ninhydrin and pyridine were from Merck 
(Germany). MCF-7 cells were purchased from Pasteur Institute (Iran).  
2.2. Synthesis of peptides 
Six linear peptides named (KW)4, (KW)5, K3W4K2, K3W4K3, W2K4W2 and W3K4W3 
were synthesized using the hydrophobic (tryptophan, W) and charged (lysine, K) amino acids 
with various designs as presented in Table 1. Overall methods were carried out according to 
the previously reported procedure [36, 41, 42]. Briefly, all peptides were synthesized 
manually by solid-phase peptide synthesis method, assembled on Rink-Amide AM resin by 
Fmoc strategy using a fritted glass vessel. Fmoc-Rink amide resin (0.049 mmol, 0.3 mmol/g) 
was swollen in DMF for approximately 1 h under dry nitrogen. Fmoc groups at N-terminal of 
the linear peptide sequence of resin were removed using piperidine in DMF (20% v/v, total 
volume of 2 ml). Following a 30-min incubation at room temperature, Fmoc-Lys (Boc)-OH 
or Fmoc-Try (Boc)-OH (0.148 mmol) was coupled to the N-terminal of Rink amide resin in 
the presence of TBTU (0.148 mmol) and DIPEA (0.148 mmol) in DMF (2 ml) by mixing for 
1.5 h. Completion of coupling was confirmed by Kaiser Test. The reaction solution was 
filtered off. Then, the obtained resin was washed with DMF (3 times each with 2 ml) and 
DCM (3 times each with 2 ml) and dried under vacuum overnight. Following the drying 
process, a fresh cleavage cocktail composed of TFA:phenol:water:TIS (88:5:5:2 v/v/v/v, total 
mixture volume of 10 ml per 100 mg peptide) was added to the resin. After shaking the 
mixture at room temperature for 2 h, the resin was collected and washed with another 2 ml 
fresh cleavage cocktail. The medium of the combined ﬁltrates were evaporated and reduced 
into a minimum volume using dry nitrogen. The crude unreacted peptide was precipitated by 
adding excess volume (ten-fold) of cold diethyl ether and centrifugation at 4000 rpm for 5 
min. Finally, the product was further washed with diethyl ether (50 ml) twice and then 
lyophilized. The schematic peptide synthesis of K3W4K3 is illustrated in Figure 1a.  
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2.3. Fluorescent labeling of the peptides on the resin 
Fmoc protecting group was removed from N-terminal of all synthesized peptides using 
piperidine solution in DMF (20%, 2 ml, 30 min). A solution of 1/1 equivalent of FITC was 
provided in pyridine/DMF/DCM (12:7:5). Then FITC was attached to the peptides through 
adding the above solution to the resin-peptides (0.049 mmol) followed by an overnight 
mixing. The FITC-labeled peptides were evaluated by Kaiser Test to confirm the success of 
labeling process [42]. The schematic synthesis of FITC-labeled K3W4K3 is demonstrated in 
Figure 1b.  
2.4. Preparation of nanoparticles  
Peptide nanoparticles were synthesized by conjugation of the linear peptides to polyglutamate 
(E), with two chain lengths of E4 (EEEE) and E8 (EEEEEEEE). The synthesized linear 
peptides dissolved in DMSO were added to the polyglutamate E4 and E8 solution in DMSO, 
at different proportions of 1:1, 1:5 and 1:10 (v/v). Then, the prepared peptide solutions were 
sonicated so that the nanoparticles were formed through self-assembly by electrostatic 
attraction. 
2.5. Determination of particle size  
Morphology and size of the synthesized CPPs and nanoparticles were investigated by 
scanning electron microscopy (SEM). Each sample was dissolved in DMSO and distilled 
water (1:99 v/v), dropped onto an aluminum plate and lyophilized. The prepared slides were 
then visualized using a Philips XL electron microscope. 
2.6. Preparation of peptide-drug conjugates  
Conjugates of peptide-drug (CPP-EPR for various CPPs) were synthesized through reaction 
of amine group in peptide and hydroxyl group in EPR drug using a succinyl spacer. When 
succinic anhydride binds to the peptides as a linker, NH2 group of the peptide is changed to a 
carboxyl moiety. N-terminal of the prepared peptides was deprotected using piperidine in 
 8 
 
DMF (20%). Then the deprotected peptides were treated with succinic anhydride (1.5 eq) and 
DIEPA (3 eq) in DMF for 2 h. The completion of the reaction was conﬁrmed by the Kaiser 
Test. Following washing the resin with DMF (3 ×2 ml) and DCM (3× 2 ml), DIEPA (0.25 
ml, 1.44 mmol) was added dropwise to the mixture of succinylated peptide and TBTU (3 eq) 
in DMF (2 ml) under stirring for 30 min. Afterward, EPR (1/5 eq) solution in DMF (2 ml) 
was added to the above mixture. The reaction mixture was stirred at room temperature for 48 
h. Following drying using nitrogen gas, peptide-EPR conjugates were cleaved from the resin 
with cleavage cocktail composed of TFA/phenol/water/Tis (88:5:5:2 v/v/v/v, total volume of 
10 ml per 100 mg peptide). Then, the corresponding nanoparticles (CPP-E4-EPR and CPP-
E8-EPR each for various CPPs) were prepared similarly as mentioned in the section 2.4. The 
schematic synthesis of K3W4K3-EPR conjugate is shown in Figure 1c. 
2.7. Drug loading measurement 
UV spectra were obtained in order to evaluate the conjugation of EPR to various CPPs using 
a UV spectrophotometer. Afterward, absorbance of the unreacted EPR for each sample and 
the standard solution (first EPR concentration) were measured at the wavelength of 504 nm. 
Loading of EPR (%) was calculated from Equation (1). 
 Equation (1) 
Where Af and As represent the optical absorbance of the sample and the standard, 
respectively. 
2.8. Cell culture  
Cellular studies were performed using MCF-7 (human breast adenocarcinoma) cell line. The 
cells were cultured on cell culture ﬂasks in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS; Gibco, USA) and 1% antibiotic–antimycotic (Penicillin–Streptomycin; 
Gibco, USA) in an incubator (5% CO2 ) at 37 °C. 
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2.9. Cytotoxicity and anti-proliferative assay  
The MTT assay was carried out to evaluate and compare the cytotoxicity and anti-
proliferative activity of various samples (different CPPs, CPPs-E4 and –E8 nanoparticles for 
cytotoxicity; different CPPs, CPPs-EPR, CPPs-E4-EPR, CPPs- E8-EPR and EPR alone for 
anti-proliferative activity) each at different concentrations. MCF-7 cell suspension at a 
density of 2 × 104 cells/well was seeded into 96-well microplates. Following incubation at 37 
ºC and 5% CO2 for 24 h and medium aspiration, the cells were treated with the 1/10 diluted 
samples in serum-free culture medium each at different final concentrations of 5, 10 and 25 
μM for cytotoxicity and 1, 5, 10 and 25 μM for anti-proliferative assay. The cells were 
incubated for 24 h or 48 h, and then the medium was aspirated and replaced with 50 µl of 
MTT solution (2 mg/ ml). After 4 h incubation, the medium was aspirated again and 
insoluble formazan crystals in each well were dissolved in mixture of dimethyl sulfoxide 
(DMSO, 200 µl) and Sorensen’s phosphate buffer (25 µl). The absorbance was measured by 
a microplate reader (Bio-Tek, USA) at a wavelength (λ) of 570 nm with reference to 650 nm. 
All of the results were blank corrected. The experiment was run for 6 replicates. Anti-
proliferative activity was calculated according to Equation (2). 
              
Equation (2)  
 
Where AS570 and AS650 correspond to the absorbance of treated samples at the respective λ = 
570 and 650 nm; AC570 and AC650 are the corresponding absorbance of untreated control 
cells.  
2.10. Fluorescence microscopy  
The cellular uptake of CPPs and the corresponding nanoparticles were visualized using 
fluorescence microscopy. MCF-7 cells were seeded on the coverslips placed inside the six 
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well plates at a density of 1 × 105 cells per well and incubated at 37 ºC and 5% CO2 for 24 h. 
Then, the cells were treated with the FITC-CPPs and FITC-CPPs-E8 nanoparticles in serum-
free culture medium each at the concentration of 10, 25 and 50 μM and incubated for 2 h. 
Subsequently, the medium of each well was aspirated and the cells were washed three times 
with cold phosphate buffered saline (PBS). For fixing the cells, 200 µl of 2% formaldehyde 
solution in PBS was added to each well and incubated at 37 °C for 15 min followed by 
washing three times with PBS. Then, the samples were visualized by a fluorescence 
microscope (Olympus IX81, Olympus Optical Co. Ltd., Japan).  
2.11. Cell uptake quantification by flow cytometry 
For cellular uptake quantification, flow cytometry assay was performed. MCF-7 cells were 
seeded in 6-well plates at a density of 2 × 105 cells/well and incubated at 37 ºC and 5% CO2 
for 24 h. Following culture medium aspiration and washing with PBS, the cells were treated 
with FITC-CPPs and FITC-CPPs-E8 nanoparticles in serum-free culture medium each at 
concentrations of 10, 25, and 50 μM. After 2 h incubation at 37 °C, the cells were washed 
three times with PBS and detached from the well by 3-min incubation at 37 °C with 0.53 mM 
of 0.25% trypsin/EDTA. Then, the cells were harvested, centrifuged, resuspended in 0.5 ml 
cold PBS and homogenized by pipetting several times. The cells were kept on ice until 
measurement of the treated cell-associated fluorescence intensity of FITC at the emission 
wavelength of 519 nm through FL1 channel for total of 10,000 events (cells/sample) using a 
FACSCalibure flow cytometer (Becton, Dickinson, USA). Cell Quest software (Becton, 
Dickinson, USA) was used for data acquisition. The analysis of fluorescence intensities was 
performed subsequently via the above mentioned software for the gated singlet cells.  
2.12. Statistical analysis 
The data were expressed as mean ± standard deviation of 3 to 6 determinations. Statistical 
analysis was performed using Graphpad Prism Software Inc. version 5.04 (Inc. La Jolla, CA, 
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USA). Different samples were compared using two-way analysis of variance (ANOVA). The 
differences were quoted statistically significant where P < 0.05. The significance level for 
pair wise comparisons was adjusted by Bonferroni method using Student t-test. 
3. Results 
Different linear peptides were synthesized on the Rink amide resin. Peptide synthesis was 
confirmed using Kaiser Test. In the next step, FITC was coupled to the synthesized peptides 
to investigate their uptake efficiency. FITC labeling was also confirmed by Kaiser Test. 
CPPs-Drug conjugates (CPPs-EPR) were then prepared using a succinic linker. CPPs, FITC-
CPPs and CPPs-EPR were cleaved from the resin using the cleavage cocktail. EPR 
conjugation to CPPs and EPR loading were evaluated by UV spectrophotometry. Afterward, 
peptide nanoparticles were synthesized by conjugation of the peptides to poly glutamate (E), 
with two chain lengths, E4 and E8. Different synthesized CPPs and the corresponding 
nanoparticles were finally characterized by scanning electron microscopy (supplementary 
data, Figure S1), cytotoxicity, cellular uptake and anti-proliferative activity 
3.1. Cytotoxicity  
As an efficient delivery vector of anti-cancer drugs, blank CPPs and nanoparticles must have 
low levels of toxicity against cells. Therefore, the cytotoxicity of all synthesized CPPs and 
the corresponding nanoparticles (E4 and E8) were evaluated in MCF-7 cancer cells as a 
function of concentrations (5, 10 and 25 µM) after 24 and 48 h incubation time. For blank 
peptides, i.e. CPPs, cytotoxicity was concentration dependent (P<0.001). The toxicity results 
for all of the nanoparticles showed that an increase in the concentration of peptides resulted 
in an increase in the toxicity after incubation for 24 (supplementary data, Figure S2) and 48 h 
(Figure 2). The increase in the toxicity of nanoparticles found to be statistically significant 
(P<0.0001). Following 24 h of incubation of the peptides with MCF-7 cells, all of the CPPs 
showed low cytotoxicity (< 20%) at the concentration of 5 µM. (KW)5, K2W4K2 and 
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W3K4W3 showed the lowest cytotoxicity (16%, 21% and 22%, respectively) at the 
concentration of 10 µM (P<0.001). In addition, at the highest concentration (25 µM), 
cytotoxicity of W3K4W3 was the lowest (22%) followed by (KW)5 and K3W4K3 peptides 
(32% and 35%, P < 0.00001). Incubation time also affected the cytotoxicity of the peptides. 
Increasing the incubation time from 24 (supplementary data, Figure S2) to 48 h (Figure 2) 
resulted in higher cytotoxicities (P < 0.0001). As illustrated in Figure 2a, (KW)5 showed the 
lowest cytotoxicity at concentration of 5 µM (15%, P < 0.01). The lowest cytotoxicity was 
observed for K2W4K2 and K3W4K3 (25% and 26%, p < 0.001) when the concentration was 
10 µM. In the cases of (KW)5 and K3W4K3 (42% and 42%, P < 0.01) the lowest toxicity 
was obtained at 25 µM. Binding of E4 to peptides led to a significant reduction in the 
cytotoxicity at different concentrations for both 24 (P<0.0001) and 48 h (P<0.001) incubation 
times (Figure 2b). As demonstrated in Figure 2c, binding of E8 to peptides also resulted in a 
significant decrease in the cytotoxicity at different concentrations for all nanoparticles at the 
both incubation times, 24 and 48 h (P < 0.00001 and P < 0.0001). Interestingly, CPPs-E8 
nanoparticles showed lower cytotoxicity than CPPs-E4 nanoparticles (P < 0.001). Therefore, 
CPPs-E8 nanoparticles possessed the lowest cytotoxicity among all nanoparticles. All of 
CPPs-E8 nanoparticles showed very low cytotoxicity (<20%) even at the highest 
concentration (25 µM) except (KW)4-E8 (at 10 and 25 µM) and K2W4K2-E8 (just at 25 
µM). 
3.2. Cellular uptake by fluorescence microscopy 
Thecellular uptake (intracellular localization) was first visualized by fluorescent microscopy. 
MCF-7 cells were incubated with various FITC-CPPs and FITC-CPPs-E8 at concentrations 
of 10, 25, and 50 µM for 2 h. As illustrated in Figure 3, cell treatments with high level 
concentrations of the samples (25 μM, supplementary data Figure S3; and 50 μM, Figure 3) 
led to increase the cellular uptake in comparison with lower concentration (10 μM, Figure 3) 
 13 
 
for both CPPs and nanoparticles. Besides, it was indicated that CPPs and CPPs-E8 
nanoparticles of K3W4K3, W3K4W3, (KW)5 and (KW)4 accumulated in the nucleus of the 
cells, while K2W4K2 peptide and its corresponding nanoparticle localized in the cytoplasm. 
It was demonstrated that W2K4W2 (both peptide and its nanoparticles) had the lowest 
cellular uptake. 
3.3. Cellular uptake by flow cytometry 
Flow cytometry was performed in order to evaluate and compare the cellular uptake ability of 
different peptides and their nanoparticles (FITC-CPPs and FITC-CPPs-E8 nanoparticles). 
Just like fluorescence microscopy, MCF-7 cells were incubated with different concentrations 
of the samples for 2 h at 37 ºC. As shown in Figure 4, the uptake was concentration 
dependent for all of the CPPs and nanoparticles. In other words the percentage of cellular 
fluorescence increased with increasing the concentration up to 25 µM (P<0.0001). At this 
concentration, the cell fluorescence reached the maximum percentage (about 100%) for all of 
the CPPs except W2K4W2 (Figure 4d) which was very low (about 20%). By increasing the 
concentration from 25 µM to 50 µM, the cell fluorescence remained stable (at plateau) for 
K3W4K3 (Figure 4a), W3K4W3 (Figure 4b) and K2W4K2 (Figure 4c). However, in the case 
of (KW)4 (Figure 4e) and (KW)5 (Figure 4f) the cell fluorescence decreased to about 75%. 
Among all of the CPPs, W2K4W2 (Figure 4d) exhibited the lowest uptake (P < 0.00001). For 
all of the nanoparticles (Figure 4), cellular uptake was lower compared to their corresponding 
CPPs at the concentration of 10 µM (P < 0.0001) and 25µM (P < 0.001). The fluorescent 
signal of K3W4K3-E8 (Figure 4a), K2W4K2-E8 (Figure 4b) and W3K4W3-E8 (Figure 4c) 
reached the same percentage with the corresponding CPPs, i.e. the maximum percentage of 
approximately 100% at the concentration of 50 µM and there was no significant difference 
between each of the mentioned CPPs and its nanoparticle (P>0.05). Cellular uptake of 
(KW)4-E8 (Figure 4e) and (KW)5-E8 (Figure 4f) was significantly higher in comparison 
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with their corresponding CPPs at the concentration of 50 µM (P < 0.0001 for both). 
Although, the cell uptake of W2K4W2-E8 (Figure 4d) was significantly higher than its 
corresponding CPP (W2K4W2) at the concentrations of 25 μM (P < 0.0001) and 50 μM (p < 
0.0001), it still exhibited the lowest percentage of cellular uptake compared to all other CPPs-
E8 nanoparticles (P<0.00001). Flow cytometry histograms of K3W4K3 and K3W4K3-E8 
each at various concentrations of 10, 25 and 50 µM are presented in Figure 5.  
3.4. Drug loading measurement 
Following the conjugation of EPR to different CPPs, conjugation was confirmed using UV 
spectrophotometry (supplementary data, Figure S4).  
3.5. Antitumor activity of drug loaded CPPs 
To determine whether the synthesized peptides and nanoparticles can be utilized for delivery 
of biologically relevant doses of EPR to cells, EPR was conjugated to them and the antitumor 
(anti-proliferative) activity of EPR was then examined and compared in MCF-7 cells at 
various concentrations. As illustrated in Figure S5a (24 h, supplementary data) and Figure 6 
(48 h), even the low concentration of 1 µM resulted in a significant increase in antitumor 
activity. As demonstrated in Figure 6 (48 h), anti-proliferative activity was concentration 
dependent which increased by increasing the concentration (P<0.001). Moreover, incubation 
time also led to higher anti-proliferative activity (P < 0.01, supplementary data, Figure S5 for 
24h; Figure 6 for 48h). Following the conjugation of EPR to the CPPs, CPPs-E4 and CPPs-
E8 nanoparticles, the anti-proliferative activity of the drug increased significantly (P<0.001) 
at the highest concentration (25 µM). Free drug (EPR) showed 63% anti-proliferative activity 
(37% cell viability) at the concentrations of 25 µM. The anti-proliferative activity increased 
to 64%-79% and 77%-91% (Figure 6a) for all CPPs-EPR conjugates at 25 µM at the 
respective incubation times of 24 (P< 0.05, supplementary data, Figure S5a) and 48 h (P < 
0.01, Figure 6a). Among the six CPP-EPR conjugates at 25 µM concentration, K3W4K3-
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EPR exhibited the highest anti-proliferative activity (80%) and W2K4W2-EPR as well as 
(KW)4-EPR possessed the lowest anti-proliferative activity (62%) after 24 h incubation 
(supplementary data, Figure S5a). Following the increase of incubation time to 48 h at 25 µM 
concentration, K3W4K3-EPR and W2K4W2-EPR showed the highest (90%) and the lowest 
(74%) anti-proliferative activity, respectively, as demonstrated in Figure 6a. CPPs-EPR-
nanoparticles displayed higher anti-proliferative activity compared to CPPs-EPR conjugates 
(p<0.05) at both incubation times especially at higher concentrations. Among all CPPs-EPR-
nanoparticles, CPPs–E8-EPR (Figure S5c (supplementary data) and Figure 6c) showed 
higher anti-proliferative activity than CPPs–E4-EPR (Figure S5b (supplementary data) and 
Figure 6b) at both incubation times (P<0.05 and P<0.01). As illustrated in Figure 6c, 
K3W4K3-E8-EPR nanoparticles exhibited the highest anti-proliferative activity (92%) for all 
CPPs-E8-EPR at 25 µM following incubation for 48 h (P < 0.05).  
4. Discussion 
Coupling of EPR to CPPs has been employed as one of the specific methods to deliver drug 
molecules into various cell lines. In the present study, different peptide sequence designs 
were chosen for peptide synthesis to examine how the presence of tryptophan and its position 
along with lysine and then peptide conjugation with 2 different chain lengths of poly 
glutamate may influence the cellular uptake and cytotoxicity of the drug.  
The cytotoxicity of the synthesized CPPs and the corresponding nanoparticles (-E4 and -E8) 
was investigated as a function of concentrations at two incubation times of 24 (supplementary 
data, Figure S2) and 48 h (Figure 2). As illustrated in Figure 2a, (KW)5 showed the lowest 
cytotoxicity at concentration of 5 µM. At the concentration of 10 µM, the lowest cytotoxicity 
was obtained by K2W4K2 and K3W4K3 and at 25 µM, the lowest cytotoxicity belonged to 
(KW)5 and K3W4K3. Taken all data together, it was shown that increasing the number of 
amino acids could result in decreased cytotoxicity so that the peptides with 10 amino acids 
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(higher number of amino acids) exhibited lower toxicity than peptides composed of 8 amino 
acids (lower number of amino acids). Displacement of lysine and tryptophan had impact on 
CPPs cytotoxicity since they showed different cytotoxicities. However, it cannot be 
concluded that the alternative design is better than the block design or vice versa. Binding of 
E4 (Figure 2b) and E8 (Figure 2c) to the peptides led to a significant decrease in the 
cytotoxicity. Interestingly, CPPs-E8 nanoparticles showed even lower cytotoxicity than 
CPPs-E4 nanoparticles. It indicates that poly glutamate chain length can be considered as an 
important factor in cytotoxicity and increasing the chain length (in range of study, from 4 to 
8) leads to a significant decrease in cytotoxicity. 
Cellular uptake of the synthesized CPPs labeled with FITC (FITC-CPPs) and the 
corresponding nanoparticles (FITC-CPPs-E8 nanoparticles) in MCF-7 cells was first 
investigated by fluorescence microscopy and then the uptake efficiency was obtained by flow 
cytometry. Based on the fluorescence microscopy images, the green fluorescence of FITC 
existed inside the cells even at the lowest concentration (10 μM). It is indicated that the 
peptides and nanoparticles possess a good ability for entering the MCF-7 cells. Increasing the 
concentration from 10 μM (Figure 3a) to 25 μM  (Figure 3) or the highest concentration of 50 
μM (supplementary data, Figure S3) led to a clear increase in cellular uptake for both CPPs 
and nanoparticles which is an indicative of the significant role of concentration. Besides, it 
was shown that CPPs and CPPs-E8 nanoparticles of K3W4K3, W3K4W3, [KW]5 and 
[KW]4 accumulated in the nucleus of the cells that is an indicative of their ability to pass 
other barriers inside the cells and reaching the nucleus, while K2W4K2 peptide and its 
corresponding nanoparticle localized in the cytoplasm. There are different uptake pathways 
for penetrating of the CPPs to the cells and it depends on different factors including peptide 
concentration, peptide sequence (structure, length and charge), and lipid composition [43]. 
K2W4K2 might be translocated by a different internalization mechanism from the other 
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peptides. The probable mechanism for this peptide might be the caveolin pathway [44]. It was 
reported that accumulation of the caveolins in the endoplasmic reticulum leads to an apparent 
concentration of the proteins in lipid droplets [45]. Hence, it is possible that K2W4K2 may be 
associated with lipid droplets or other cytoplasmic particles and this peptide might need 
longer time to enter to the nucleus [44]. Both peptide and–E8 nanoparticle of W2K4W2 
displayed the lowest fluorescence inside the cells which is possibly due to its low cellular 
uptake, which means its weak internalization into the cells.  
Based on the flow cytometry results, the uptake was concentration dependent for all of the 
CPPs and nanoparticles and increased with increasing the concentration up to 25 µM (Figure 
4). At this concentration the cell fluorescence reached the maximum percentage (about 
100%) for all of the CPPs except W2K4W2 (Figure 4d) which was as low as 20%. By 
increasing the concentration from 25 µM to 50 µM, the cell fluorescence remained stable (at 
plateau) for K3W4K3 (Figure 4a), W3K4W3 (Figure 4b) and K2W4K2 (Figure 4c); 
however, the cell fluorescence decreased to about 75% for (KW)4 and (KW)5 (Figure 4e and 
4f, respectively). For all of the nanoparticles (Figure 4), cellular uptake was lower in 
comparison with their corresponding CPPs at the concentration of 10 µM and 25 µM. The 
fluorescent signal of K3W4K3-E8 (Figure 4a), K2W4K2-E8 (Figure 4b) and W3K4W3-E8 
(Figure 4c) reached the same percentage with the corresponding CPPs (100%) at the 
concentration of 50 µM and there was no significant difference between each of the 
mentioned CPPs and its nanoparticle at this concentration. Cellular uptake of (KW)4-E8 
(Figure 4e) and (KW)5-E8 (Figure 4f) was obtained significantly higher (uptake of 90%) in 
comparison with their corresponding CPPs (uptake of 75%) at the concentration of 50 µM. 
Although, the cell uptake of W2K4W2-E8 (Figure 4d) was significantly higher than its 
corresponding CPP (W2K4W2) at the concentrations of 25 μM and 50 μM, it still exhibited 
the lowest percentage of cellular uptake compared to all other CPPs-E8 nanoparticles which 
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is in agreement with the result of fluorescence microscopy. It was reported that the addition 
of tryptophan amino acid could improve cellular uptake efficiency and peptides with 
sequences containing tryptophans in the middle or along the peptide sequence resulted in 
high uptake [40]. Interestingly, it was obtained that the cytotoxicity decreased markedly and 
the cellular uptake increased partly following the coupling of E8 and E4 to CPPs and 
synthesizing the nanoparticles. CPPs –E8 showed less cytotoxicity and more improved 
delivery of EPR compared to CPPs –E4. CPPs present a great diversity in terms of amino 
acid composition and 3D structure, with examples of cationic, anionic, and neutral sequences 
showing varying degrees of hydrophobicity and polarity. The various CPPs sequences may 
lead to different modes of cellular uptake, and different levels of uptake. CPPs can traverse 
membranes in order to enter cells via different uptake mechanisms. Despite many studies on 
CPPs, the mechanisms by which CPPs enter the cells have not been completely understood. 
For a long time, it was believed that CPPs would most likely enter cells by a passive process, 
which is temperature and receptor independent [46]. Endocytosis, being the most common 
process used by cells to absorb materials from their environment, can also be used as the 
translocation pathway of CPPs into cells [46, 47]. Endocytosis is a generic term for several 
different processes, such as phagocytosis for large particles and pinocytosis for smaller ones, 
as well as receptor-mediated endocytosis in which clathrin or caveolin pits are involved [24, 
43, 46]. Several receptors were uncovered to be involved in internalization of CPPs, such as 
chemokine receptors, syndecans [48, 49], neuropilins [50, 51], the family of integrins [52], 
homing sequences, and positively-charged scavenger receptors [53, 54]. Micropinocytosis 
appears to be another pathway for some of CPPs. that is mediated by positively charged 
residues interacting with phosphoinositides. A nonendocytotic, receptor-free, energy-
independent cellular process is another mechanism of the CPP translocation across biologic 
membranes, including formation of inverted micelles, direct translocation through the lipid 
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bilayer, and pore formation on the membrane [46, 47, 55, 56]. CPPs with high content in 
cationic residues are first absorbed at the cell surface to the numerous anionic moieties, such 
as sialic or phospholipidic acid or heparan sulfate proteoglycans [46, 57].  Which of these 
mechanisms a CPP will use is dependent on such parameters as concentration, size (with 
cargo), temperature, cell type, and modifications of CPPs or their cargo [43, 46, 55]. 
The cell membrane is a heterogeneous double layer where some regions are denser and some 
others have more fluidity due to the presence of different lipid compositions. These properties 
in turn along with CPPs’ properties can result in a variety of signaling pathways and different 
levels and modes of uptake which depend upon the conditions used for testing CPPs [58, 59, 
60, 61, 62]. Since the synthesized amphipathic peptides commonly have positive charge and 
cancer cell membranes typically carry a net negative charge [63], the elevated expression of 
anionic molecules such as proteoglycans [64] and the electrostatic attraction between them is 
believed to play a conclusive role in the cellular uptake of this peptides. Different studies 
indicated that endocytosis and direct translocation through the cellular membrane are the 
major mechanisms used by CPPs to gain entry into the cell [30].  
To determine if the synthesized peptides and nanoparticles can be utilized for the delivery of 
biologically relevant doses of EPR to cells, EPR was conjugated to these synthesized peptides 
using succinyl hydrolysable spacer which allows the drug to release after the uptake into the 
cells [65]. The antitumor activity of free drug (EPR) was then examined and compared to 
CPPs-EPR conjugates and CPPs-E8-EPR nanoparticles at various concentrations in MCF-7 
cells. As demonstrated in Figure 6, anti-proliferative activity was concentration dependent 
which increased by an increase in the concentration of CPP-EPR. Moreover, incubation time 
also led to higher anti-proliferative activity. Following the conjugation of EPR to the CPPs, 
CPPs-E4 and CPPs-E8 nanoparticles, the anti-proliferative activity of the drug increased 
significantly at the highest concentration (25 µM). Free drug (EPR) showed 63% anti-
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proliferative activity. The antitumor activity increased to 63%-79% and 87%-91% (Figure 6a 
and S3a) for all CPPs-EPR conjugates at 25 µM at the respective incubation time of 24 and 
48 h. It can be concluded that at the highest concentration, peptides improves the antitumor 
activity of EPR in comparison to free EPR. The enhanced antitumor activity of CPPs-EPR 
conjugates in comparison with free EPR can be related to their high cellular uptake tendency. 
Among all CPP-EPR conjugates at 25 µM, K3W4K3-EPR exhibited the highest anti-
proliferative activity and W2K4W2-EPR as well as (KW)4-EPR possessed the lowest anti-
proliferative activity after 24 h incubation. Following the increase in incubation time to 48 h, 
K3W4K3-EPR and W2K4W2-EPR showed the highest and the lowest anti-proliferative 
activity), respectively (Figure 6a). The lowest antitumor activity of W2K4W2-EPR can be 
due to its lowest cellular uptake demonstrated by both fluorescence microscopy and flow 
cytometry. CPPs-EPR-nanoparticles displayed higher anti-proliferative activity compared to 
free EPR and also CPPs-EPR conjugates at both incubation times especially at higher 
concentrations while overall they showed very low cytotoxicity even at the highest 
concentration. Therefore, their enhanced anti-proliferative activity is possibly related to their 
high cellular uptake tendency. Among all CPPs-EPR-nanoparticles, CPPs–E8-EPR (Figure 
S5c (supplementary data) and Figure 6c) showed higher anti-proliferative activity than CPPs–
E4-EPR (Figure S5b (supplementary data) and Figure 6b) at both incubation times. As 
illustrated in Figure 6c, K3W4K3-E8-EPR nanoparticles exhibited the highest anti-
proliferative activity (92%) of all CPPs-E8-EPR at 25 µM following incubation for 48 h. 
Furthermore, K3W4K3-E8 showed the lowest cytotoxicity of among all products produced in 
the present study. Generally, CPPs and CPPs-E4 or –E8 nanoparticles displayed improved 
anti-proliferative activity compared to free EPR (at higher concentrations). This enhanced 
antitumor activity could be attributed to the high cellular uptake tendency of the synthesized 
peptides or nanoparticles [66]. Nanoparticles showed greater intracellular uptake and less 
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cytotoxicity. Moreover, the effect of EPR was better for nanoparticles compared to CPPs at 
higher concentration levels. The reason for this may be due to the changes in conformation 
and the charge of peptides of nanoparticles and diverse uptake pathways following an 
interaction with cell membrane.  
It was reported that the endocytosis pathway may be responsible for the vast majority of 
cationic peptide internalization at low concentrations. It was shown that at low concentration, 
endocytosis of peptides could occur which may result in endosomal entrapped peptides and 
possible metabolic degradation [67, 68]. However numerous evidences suggest that direct 
penetration does occur at high concentrations (above 10 µm) [67, 68]. Pathways of the uptake 
depended concentration can explain variation of cytotoxicity and uptake of peptides. As 
shown, the uptake of peptides and following antitumor activity of EPR-CPPs and EPR-CPPs-
E8 increased at high concentrations and this can possibly due to direct translocation at high 
concentration. 
5. Conclusion 
In summary, different linear peptides were successfully synthesized separately or conjugated 
to EPR. Poly glutamate (E4 or E8) was also conjugated to the peptides and peptides-EPR to 
prepare nanoparticles. The effect of various CPPs and their nanoparticles was then evaluated 
against a breast cancer cell line (MCF-7). Results showed that cytotoxicity was concentration 
and time dependent. Binding of poly glutamate to CPPs resulted in a significant decrease in 
cytotoxicity. Interestingly, CPPs-E8 nanoparticles showed lower cytotoxicity than CPPs-E4. 
Uptake was concentration dependent for all of the CPPs and nanoparticles up to 25 µM. 
Among all of the CPPs, W2K4W2 exhibited the lowest uptake. K3W4K3-E8, K2W4K2-E8 
and W3K4W3-E8 reached the highest uptake at the concentration of 50 µM and there was no 
significant difference between each of them and their nanoparticles. Following the 
conjugation of EPR to the CPPs and nanoparticles, the anti-proliferative activity of EPR 
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increased significantly at the highest concentration (25 µM). CPPs-EPR-nanoparticles 
displayed higher anti-proliferative activity compared to CPPs-EPR conjugates especially at 
25 µM. Interestingly, CPPs–E8-EPR nanoparticles showed higher anti-proliferative activity 
than CPPs–E4-EPR. K3W4K3-E8-EPR nanoparticles exhibited the lowest cytotoxicity, high 
cellular uptake and the highest anti-proliferative activity at 25 µM following 48h incubation. 
Taking together the aforementioned advantages, the peptide nanoparticles are proposed as 
more potential nanosystems for cellular delivery of drugs at high concentration levels 
compared to CPPs, but they should also be tested in-vivo. 
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 Table 1. Different cell penetrating peptide amphiphiles (CPPs) synthesized in the present 
study 
CPPs Sequence design Number of amino 
acids 
Design 
(KW)4  KWKWKWKW 8 Alternative 
(KW)5 KWKWKWKWKW 10 Alternative 
K2W4K2 KKWWWWKK 8 Two-block 
K3W4K3 KKKWWWWKKK 10 Tri-block 
W2K4W2 WWKKKKWW 8 Two-block 
W3K4W3 WWWKKKKWWW 10 Tri-block 
Note: W and K represent tryptophan (hydrophobic amino acid) and lysine (charged amino acid), 
respectively. 
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Table 2. The percentage of drug (EPR) loading for different peptide-EPR conjugates (CPPs-
EPR)  
CPPs-EPR Drug loading ± SD (%) 
(KW)4  77.0 ± 4.2  
(KW)5 74.0 ± 3.0 
K2W4K2 50.2 ± 2.6 
K3W4K3 58.0 ± 2.3 
W2K4W2 51.0 ± 4.6 
W3K4W3 61.1 ± 4.6 
Note: W and K represent tryptophan (hydrophobic amino acid) and lysine (charged amino acid), 
respectively. 
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Figure captions 
Figure 1. The schematic peptide synthesis of K3W4K3 (a), the schematic synthesis of FITC-
labeled K3W4K3 (b) and the schematic synthesis of K3W4K3-EPR conjugate (c). 
Figure 2. MTT-based cytotoxicity of different CPPs (a), CPPs-E4 nanoparticles (b) and 
CPPs-E8 nanoparticles (c) at various concentrations (5, 10 and 25 µM) after 48h incubation 
in MCF-7 cell line at 37ºC. Data represent Mean ± SD for 6 replicates. 
Figure 3. Fluorescence microscopy images of MCF-7 cells incubated with FITC-labeled 
CPPs and their corresponding nanoparticles (CPPs-E8) at concentration of 10 (a) and 50 (b) 
µM after 2h incubation at 37ºC.  
Figure 4. Cellular uptake (%) of FITC-CPPs and the corresponding nanoparticles (FITC-
CPPs-E8) at different concentration of 10, 25, and 50 µM after 2h incubation in MCF-7 cell 
at 37°C. Data represent Mean ± SD for 3 replicates. FITC-CPPs and FITC-CPPs-E8 
nanoparticles are presented by black line with symbol of ■ and red dot line with symbol of ●, 
respectively.  
Figure 5. Flow cytometry histograms of MCF-7 cells treated for 2 h with K3W4K3 (left) and 
K3W4K3-E8 (right) at various concentrations of 10 (a and d), 25 (b and e) and 50 (c and f) 
µM. First peak (gray color) corresponds to untreated control cells. 
Figure 6. MTT-based anti-proliferative activity of different CPPs-EPR (a), CPPs-E4-EPR (b) 
and CPPs-E8-EPR (c) in comparison with free drug (EPR) at various concentrations (1, 5, 10 
and 25 µM) after 48 h incubation in MCF-7 cells at 37º C. Data represent  Mean ± SD for 6 
replicates.  
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